


# Stabilis



## Pentobarbital sodium



Noms commerciaux

Nembutal

Etats Unis d'Amérique



### Stabilité des solutions

	∅	50 mg/ml	25°C	?	31			1628
	∅	50 mg/ml	25°C	?	31			1628
	∅	50 mg/ml	25°C	?	100			4303



### Facteur influençant la stabilité







				3379
--	--	--	--	------



### Compatibilités

Pentobarbital sodium : 2 mg/ml Aciclovir sodium : 5 mg/ml		336
Pentobarbital sodium Chlorpromazine hydrochloride		3596

		Pentobarbital sodium Droperidol		4009
		Pentobarbital sodium : 5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Pentobarbital sodium : 5 mg/ml		1415
		Pentobarbital sodium : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Pentobarbital sodium Atracurium besylate		3676
		Pentobarbital sodium : 28.6 mg/ml Atropine sulfate : 0.17 mg/ml		1203
		Pentobarbital sodium : 25 mg/ml Cimetidine hydrochloride : 75 mg/ml		1203
		Pentobarbital sodium Cimetidine hydrochloride		3592
		Pentobarbital sodium Clindamycin phosphate		3526
		Pentobarbital sodium Erythromycin lactobionate		3674
		Pentobarbital sodium Esketamine		4700
		Pentobarbital sodium Fentanyl citrate		3503
		Pentobarbital sodium Glycopyrronium bromide		3599
		Pentobarbital sodium : 5 mg/ml Linezolid : 2 mg/ml		1925
		Pentobarbital sodium Morphine sulfate		3531
		Pentobarbital sodium : 48 mg/ml		3379
		Pentobarbital sodium Hydroxocobalamin		3932
		Pentobarbital sodium Ketamine hydrochloride		3501
		Pentobarbital sodium : 5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Pentobarbital sodium : 33.33 mg/ml Midazolam hydrochloride : 1.67 mg/ml		404
		Pentobarbital sodium : 25 & 50 mg/ml Nalbuphine hydrochloride : 2,5 >> 10 mg/ml		616
		Pentobarbital sodium Norepinephrine bitartrate		642
		Pentobarbital sodium Pethidine hydrochloride		3525
		Pentobarbital sodium : 50 mg/ml Propofol		660
		Pentobarbital sodium : 5 mg/ml Propofol : 10 mg/ml		300
		Pentobarbital sodium Suxamethonium chloride		3631
		Pentobarbital sodium Trimebutine		3931

	Pentobarbital sodium : 5 mg/ml Valproic acid : 2 & 20 mg/ml		4428
	Pentobarbital sodium : 0.2 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
	Pentobarbital sodium : 5 mg/ml		301



## Voie d'administration



## Bibliographie

	Type	Source
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
616	Revue	Jump WG, Plaza VM, Poremba A. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm 1982 ; 39: 841-843.
642	Revue	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1203	Revue	Yuhas EM, Lofton FT, Baldinus JG, Mayron D. Cimetidine hydrochloride compatibility with preoperative medications. Am J Hosp Pharm 1981 ; 38: 1173-1174.


1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1628	Revue	Das Gupta V. Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes. Int J Pharm Compound 2001 ; 5: 482-484.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3501	Laboratoire	Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011
3503	Laboratoire	Fentanyl - Summary of product Characteristics Hameln Pharmaceuticals 2012
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3592	Laboratoire	Cimetidine - Résumé des caractéristiques du produit Sandoz 2008
3596	Laboratoire	Chlorpromazine (Largactil®) - Summary of Product Characteristics Sanofi 2014
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3631	Laboratoire	Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit Aguettant 2016
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3676	Laboratoire	Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014
3931	Laboratoire	Trimébutine (Débridat®) - Résumé des caractéristiques du produit Pfizer Laboratoire 2016
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
4009	Laboratoire	Droperidol - Résumé des Caractéristiques du Produit
4303	Revue	Pandhara C, McKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385.

4428	Revue	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4700	Laboratoire	Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022

# Stabilis









## Pentobarbital sodium



### Stabilité des préparations

		100 mg ® = ?	OraPlus® / OraSweet SF® (1:1) >> 4 ml	22°C	?	21			3845
		100 mg ® = ?	Orablend SF® >> 4 ml	22°C	?	14			3845
		100 mg ® = ?	Inorpha® >> 4 ml	22°C	?	60			3845
		100 mg ® = ?	Eau purifiée >> 4 ml	4°C	?	60			3845
		100 mg ® = ?	Orablend SF® >> 4 ml	4°C	?	14			3845

		100 mg ® = ?	Inorpha® >> 4 ml	4°C	?	60				3845
		100 mg ® = ?	OraPlus® / OraSweet SF® (1:1) >> 4 ml	4°C	?	30				3845



## Bibliographie

	Type	Source
3845	Revue	Schlatter J, Kabiche S, Balde I-S, Majoul E, Cisternino S, Fontan J.E. Stability of Pentobarbital in Water and Oral Pediatric Suspensions. Ann Pharmacotherapy 2016 ; 50: 245-246



# Dictionnaire

Anesthésique général	Injectable
Noms commerciaux	Stabilité des solutions
Contenant	Molécule
Concentration	Température
Conservation	Durée de stabilité
Biosimilaire	Données conflictuelles
Bibliographie	Verre
Aucun	Non précisée
Jour	Seringue polypropylène
Facteur influençant la stabilité	Solvant
Nutrition parentérale (mélange binaire)	Provoque
Dégradation	Compatibilités
Molécule	Compatible
Glucose 5%	Incompatibilité non précisée
Incompatible	Précipitation immédiate
Chlorure de sodium 0,9%	Instabilité de l'émulsion immédiate
Nutrition parentérale (mélange ternaire)	Perte de turbidité
Précipitation en 24 heures	Turbidité immédiate
Instabilité de l'émulsion à 4 heures	NaCl 0,9% ou glucose 5%
Voie d'administration	Intraveineuse
Intramusculaire	Bibliographie
Solution buvable	Stabilité des préparations
Origine	Excipient
Flacon plastique	Poudre
Dictionnaire	